US FDA Vaccine Approvals Set Up CDC Votes On Merck’s Capvaxive, Moderna’s mResvia

 
• By Bridget Silverman

Advisory Committee on Immunization Practices expected to vote 26-28 June on use of Merck’s 21-valent pneumococcal vaccine, Moderna’s mRNA vaccine for RSV, and an expanded age range for GlaxoSmithKline’s Arexvy RSV vaccine.

Vaccine for older woman
ACIP will consider two newly approved vaccines for adults and one with an expanded indication. • Source: Shutterstock

More from Approvals

More from Product Reviews